Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 445

Results For "AI"

8377 News Found

Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil
News | June 30, 2023

Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil

The company is already marketing the 4 mg and 10 mg strengths


Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData
News | June 30, 2023

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024


GenWorks Health launches IVD tests for dengue and malaria
Healthcare | June 29, 2023

GenWorks Health launches IVD tests for dengue and malaria

Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1


Granules India and Central Bureau of Narcotics unite to tackle drug abuse
News | June 29, 2023

Granules India and Central Bureau of Narcotics unite to tackle drug abuse

Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society


Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials
Clinical Trials | June 29, 2023

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials


AstraZeneca announces US$400 million investment in reforestation and biodiversity
News | June 28, 2023

AstraZeneca announces US$400 million investment in reforestation and biodiversity

New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia


Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity
News | June 28, 2023

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite


Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
News | June 28, 2023

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement


Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction
News | June 28, 2023

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program


Lonza collaborates with Vertex on cell, gene technologies manufacturing
News | June 28, 2023

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)